ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
망막 정맥 폐색증 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 10.3%로 252억 5,000만 달러로 성장합니다. 예측 기간의 성장은 혁신적인 치료 접근법, 원격의료 및 원격 모니터링, 맞춤형 의료, 규제 당국의 승인에 기인합니다. 예측 기간의 주요 동향으로는 비침습적 치료 옵션, 유전자 치료의 획기적인 발전, 환자 중심 치료, 디지털 헬스 툴 등이 있습니다.
향후 5년간 성장률 10.3%라는 예측은 지난번 예측보다 0.2% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 인상은 스위스나 아일랜드에서 조달하는 항혈관내피성장인자 주사제나 레이저 광응고장치의 가격을 상승시켜 치료비를 악화시키고 시력 결과를 악화시킴으로써 미국 환자들에게 부담을 줄 가능성이 높습니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
안질환 유병률 증가가 예상에 따라 안구 약물전달 시장의 향후 성장이 기대됩니다. 안질환은 안구, 시력 또는 안구 주변 구조에 영향을 미치는 광범위한 증상을 포함합니다. 신정맥폐색증 발병률 증가는 신정맥폐색증 시장 성장에 기여하고 있으며, 이에 따라 이 질환을 치료할 수 있는 혁신적인 진단 및 치료법에 대한 수요가 증가하고 있습니다. 예를 들어 스위스에 본부를 둔 유엔기구인 세계보건기구(WHO)는 2023년 3월, 전 세계에서 약 22억 명이 근시 또는 원시 시력 장애를 경험할 것으로 추정하고 있습니다. 백내장(9,400만 명)과 교정되지 않은 굴절이상(8,840만 명)이 시각장애와 시력장애의 주요 원인입니다. 또한 녹내장(770만 건), 각막혼탁(420만 건), 당뇨망막병증(390만 건), 트라코마(200만 건) 등도 시력저하의 원인이 되고 있습니다. 따라서 안질환의 유병률 증가는 망막정맥폐쇄증 시장의 원동력이 될 것으로 보입니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 망막 정맥 폐색증 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 망막 정맥 폐색증 시장 : 성장률 분석
세계의 망막 정맥 폐색증 시장 실적 : 규모와 성장, 2019-2024
세계의 망막 정맥 폐색증 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 망막 정맥 폐색증 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 망막 정맥 폐색증 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
망막 동맥 분지 폐색증
중추성 망막 정맥 폐색증
세계의 망막 정맥 폐색증 시장 : 상태별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
비허혈성
허혈성
세계의 망막 정맥 폐색증 시장 : 진단별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
광간섭 단층촬영
안저 검사
Fluorescein Angiography
세계의 망막 정맥 폐색증 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
항혈관 내피 증식 인자
코르티코스테로이드약
레이저 망막 광응고술
세계의 망막 정맥 폐색증 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원과 진료소
조사·학술 센터
기타 최종사용자
세계의 망막 정맥 폐색증 시장 : 서브 세분화 망막 동맥 분지 폐색증(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
비허혈성 망막 동맥 분지 폐색증
허혈성 망막 동맥 분지 폐색증
세계의 망막 정맥 폐색증 시장 : 서브 세분화 중추성 망막 정맥 폐색증(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
비허혈성 중추성 망막 정맥 폐색증
허혈성 중추성 망막 정맥 폐색증
제7장 지역별·국가별 분석
세계의 망막 정맥 폐색증 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 망막 정맥 폐색증 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
망막 정맥 폐색증 시장 : 경쟁 구도
망막 정맥 폐색증 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Bristol-Myers Squibb Company
Amgen Inc.
Allergan PLC
Regeneron Pharmaceuticals Inc.
Biogen Idec Inc.
Vertex Pharmaceuticals Inc.
Bausch Health Companies Inc.
Carl Zeiss AG
Santen Pharmaceutical Co. Ltd.
Lumenis Ltd.
Coherus Biosciences Inc.
Genentech Inc.
Topcon Corporation
Nidek Co. Ltd
IRIDEX Corporation
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
망막 정맥 폐색증 시장 2029 : 새로운 기회를 제공하는 국가
망막 정맥 폐색증 시장 2029 : 새로운 기회를 제공하는 부문
망막 정맥 폐색증 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Retinal vein occlusion (RVO) is a medical condition occurring when a blockage or hindrance in the veins that carry blood away from the retina, the light-sensitive tissue at the rear of the eye. The prevention of RVO involves managing other illnesses related to blood vessels that increase the risk of RVO development. This management includes adopting a low-fat diet, engaging in regular exercise, and maintaining a healthy body weight.
The main categories of retinal vein occlusion encompass branch retinal artery occlusion and central retinal vein occlusion. Branch retinal artery occlusion is characterized by reduced arterial blood flow to a branch of the central retinal artery, resulting in ischemic damage in the affected area of the retina. Treatment for this condition typically involves ocular hypotensive drugs like topical timolol or intravenous (IV) and oral acetazolamide. These conditions are further divided into non-ischemic and ischemic types, with diagnosis relying on methods such as optical coherence tomography, fundoscopic examination, and fluorescein angiography. Treatment strategies encompass antivascular endothelial growth factor therapy, corticosteroid medications, and laser retinal photocoagulation, with end users including hospitals, clinics, research and academic centers, among others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The retinal vein occlusion market research report is one of a series of new reports from The Business Research Company that provides retinal vein occlusion market statistics, including retinal vein occlusion industry global market size, regional shares, competitors with a retinal vein occlusion market share, detailed retinal vein occlusion market segments, market trends and opportunities and any further data you may need to thrive in the retinal vein occlusion industry. This retinal vein occlusion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The retinal vein occlusion market size has grown rapidly in recent years. It will grow from $15.43 billion in 2024 to $17.03 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to aging population, advancements in diagnostic imaging, pharmaceutical developments, increased diabetes prevalence.
The retinal vein occlusion market size is expected to see rapid growth in the next few years. It will grow to $25.25 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to innovative treatment approaches, telemedicine and remote monitoring, personalized medicine, regulatory approvals. Major trends in the forecast period include non-invasive treatment options, gene therapy breakthroughs, patient-centric care, digital health tools.
The forecast of 10.3% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of anti-Vascular Endothelial Growth Factor injectables and laser photocoagulation devices sourced from Switzerland and Ireland, exacerbating treatment expenses and worsening vision outcomes. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated rise in the prevalence of eye disorders is poised to stimulate the growth of the ocular drug delivery market in the future. Eye disorders encompass a broad spectrum of conditions affecting the eyes, vision, or the structures surrounding the eyes. The increasing incidence of renal vein occlusion is contributing to the growth of the renal vein occlusion market, resulting in a heightened demand for innovative diagnostics and treatments to address this condition. For example, in March 2023, the World Health Organization, a United Nations agency based in Switzerland, estimated that globally, around 2.2 billion people will experience impairment in near- or far-sighted vision. Cataracts (94 million) and uncorrected refractive issues (88.4 million) represent the primary causes of visual impairment or impaired vision. Additionally, other common contributors to vision loss include glaucoma (7.7 million cases), corneal opacities (4.2 million cases), diabetic retinopathy (3.9 million cases), and trachoma (2 million cases). Hence, the increasing prevalence of eye disorders will be a driving force behind the retinal vein occlusion market.
The expected increase in the incidence of glaucoma is set to propel the growth of the retinal vein occlusion market in the coming years. Glaucoma is an eye condition characterized by elevated intraocular pressure within the eye, posing a risk to the optic nerve and potentially leading to vision loss or blindness if left untreated. The prevalence of glaucoma cases significantly contributes to the expansion of retinal vein occlusion, underscoring the crucial need for effective prevention and management strategies. These strategies aim to reduce the risk of retinal vein occlusion and enhance overall quality of life. For instance, as of October 2022, the BrightFocus Foundation, a U.S.-based nonprofit organization dedicated to advancing research and support for macular degeneration and glaucoma, reported a current global estimate of 80 million individuals with glaucoma, with a projected increase to over 111 million by the year 2040. Therefore, the rising incidence of glaucoma will drive the growth of the optic atrophy management market.
Companies operating within the retinal vein occlusion market are embracing innovative approaches to enhance patient care and treatment outcomes while maintaining their competitive position in the market. Progress in drug development holds the potential to expand the range of treatment options for RVO, delivering more precise and effective treatments. For instance, in April 2023, Iridex Corporation, a U.S.-based ophthalmic medical technology company, introduced the next-generation Iridex PASCAL. This cutting-edge platform integrates rapid and precise pattern scanning capabilities, endpoint management technology, pattern scanning laser trabeculoplasty, and micropulse technology into a more compact, ergonomically designed integrated laser platform. This advancement is designed to offer personalized care to patients with retinal diseases.
In April 2022, Samsung Biologics Co. Ltd., a South Korea-based biotechnology company, acquired Samsung Bioepis for $2.3 billion. This acquisition is expected to boost Samsung Bioepis' sales growth, operating margins, and capabilities in both biosimilar development and novel drug development. Samsung Bioepis Co. Ltd. is a South Korea-based biopharmaceutical company known for providing treatments for retinal vein occlusion through its biosimilar product, BYOOVIZ (ranibizumab-nuna).
North America was the largest region in the retinal vein occlusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in retinal vein occlusion report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the retinal vein occlusion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The retinal vein occlusion market consists of revenues earned by entities by providing services such as surgery and pan retinal photocoagulation. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinal vein occlusion market also includes sales of ranibizumab and aflibercept. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Retinal Vein Occlusion Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on retinal vein occlusion market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for retinal vein occlusion ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The retinal vein occlusion market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Branch Retinal Artery Occlusion; Central Retinal Vein Occlusion
2) By Condition: Non-Ischemic; Ischemic
3) By Diagnosis: Optical Coherence Tomography; Fundoscopic Examination; Fluorescein Angiography
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Retinal Vein Occlusion Market Characteristics
3. Retinal Vein Occlusion Market Trends And Strategies
4. Retinal Vein Occlusion Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Retinal Vein Occlusion Growth Analysis And Strategic Analysis Framework
5.1. Global Retinal Vein Occlusion PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Retinal Vein Occlusion Market Growth Rate Analysis
5.4. Global Retinal Vein Occlusion Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Retinal Vein Occlusion Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Retinal Vein Occlusion Total Addressable Market (TAM)
6. Retinal Vein Occlusion Market Segmentation
6.1. Global Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Branch Retinal Artery Occlusion
Central Retinal Vein Occlusion
6.2. Global Retinal Vein Occlusion Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Ischemic
Ischemic
6.3. Global Retinal Vein Occlusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Optical Coherence Tomography
Fundoscopic Examination
Fluorescein Angiography
6.4. Global Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antivascular Endothelial Growth Factor
Corticosteroid Drugs
Laser Retinal Photocoagulation
6.5. Global Retinal Vein Occlusion Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Research And Academics Centers
Other End-Users
6.6. Global Retinal Vein Occlusion Market, Sub-Segmentation Of Branch Retinal Artery Occlusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-ischemic Branch Retinal Artery Occlusion
Ischemic Branch Retinal Artery Occlusion
6.7. Global Retinal Vein Occlusion Market, Sub-Segmentation Of Central Retinal Vein Occlusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-ischemic Central Retinal Vein Occlusion
Ischemic Central Retinal Vein Occlusion
7. Retinal Vein Occlusion Market Regional And Country Analysis
7.1. Global Retinal Vein Occlusion Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Retinal Vein Occlusion Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
